Digital Phablet

Tag: prostate cancer

  • PSA Test May Predict Who Survives Advanced Prostate Cancer

    PSA Test May Predict Who Survives Advanced Prostate Cancer

    Doctors frequently monitor prostate cancer with a blood test called prostate-specific antigen (PSA). When treatment is effective, PSA levels typically decrease, but clinicians need clear targets to determine if a patient is responding adequately. A recent extensive real-world study has revealed that a PSA level dropping below 0.2 nanograms per milliliter within nine months of starting treatment can be especially meaningful for men with prostate cancer that has spread beyond the prostate. Men whose PSA levels fell under this threshold experienced significantly better survival rates.

    The study was published online in CANCER, a peer-reviewed journal of the American Cancer Society. It analyzed health records from the U.S. Veterans Health Administration, involving 4,890 patients treated between 2018 and 2023. These individuals had metastatic hormone-sensitive prostate cancer, meaning the cancer had spread but still responded to therapies that suppress or block testosterone. Since testosterone can promote prostate cancer growth, standard care often involves androgen deprivation therapy, which significantly reduces male hormone levels or inhibits their effects on cancer cells. Many doctors also combine this with additional medications to better control the disease. Despite modern treatments, patient responses vary widely, making early indicators of treatment effectiveness particularly valuable.

    PSA is a protein produced by the prostate gland, including prostate cancer cells. A decline in PSA levels after treatment generally indicates a reduction in cancer activity, but there has been ongoing debate about which specific responses best predict long-term outcomes. Previous clinical trials suggested that reaching a PSA level below 0.2 ng/mL was strongly associated with improved survival. In practice, clinicians often consider the percentage decrease in PSA, such as a 90% reduction, as another marker of response.

    In this large observational study, researchers tracked patients over a median period of around two years, during which 896 patients passed away. The findings showed that the most significant predictor of improved survival was the PSA level actually achieved. Men whose PSA dropped below 0.2 ng/mL within nine months were 54% less likely to die compared to those whose PSA did not reach that level. Interestingly, the extent of the PSA decline—such as a reduction of 90%—did not provide the same prognostic information. Patients who experienced large percentage drops but still maintained PSA levels above 0.2 ng/mL did not show improved survival, implying that the final PSA target might be more crucial than the magnitude of decline along the way.

    The study also indicated that patients receiving a combination of testosterone-lowering therapy and additional drugs that further block testosterone were more likely to reach the very low PSA goal. This supports the trend toward more intensive combination treatments for suitable patients with metastatic prostate cancer.

    Dr. Stephen J. Freedland, a urology professor at Cedars-Sinai and a physician at Durham VA Medical Center, commented that these findings endorse aiming for a PSA level below 0.2 ng/mL as a treatment goal. Patients who do not reach this level might require closer monitoring or consideration of more aggressive treatment options.

    A significant strength of the research is that it examined a large number of patients receiving routine medical care, demonstrating that real-world results align with those seen in clinical trials. However, it’s important to recognize that these findings do not necessarily prove that lowering PSA below 0.2 ng/mL will automatically extend life for every individual. This was an observational study, and often, patients who reach very low PSA levels may have cancers that are inherently more sensitive to treatment.

    Ultimately, the evidence suggests that a PSA level below 0.2 ng/mL within nine months serves as a strong marker of both treatment effectiveness and positive prognosis. Future research should explore whether adjusting therapies early for patients who do not meet this target could actually improve survival rates.

    For patients and healthcare providers, this study offers a straightforward, practical benchmark. Achieving a very low PSA early on may identify individuals performing particularly well, while not reaching this goal could prompt a re-evaluation of the current treatment plan.

  • Joe Biden’s Son Reveals Cancer Has Spread Beyond Bones and Is Extremely Painful

    Joe Biden’s Son Reveals Cancer Has Spread Beyond Bones and Is Extremely Painful

    Former U.S. President Joe Biden’s prostate cancer has advanced beyond his bones, leading to significant pain, according to his son Hunter Biden during an interview with the BBC. Hunter shared that “the cancer has metastasized into his bones and further,” describing the experience as extremely painful and debilitating in many ways. During the discussion on BBC’s Newsnight, Hunter became visibly emotional while talking about his father’s health. He added, “It’s really tough to watch and very heartbreaking,” but reassured that his father remains active and dedicated to serving the country. A representative for the 83-year-old Biden chose not to comment on the interview the following day.

    Biden disclosed in May 2025, shortly after stepping down from the presidency, that he had been diagnosed with an aggressive prostate cancer that had already spread to his bones. Since then, he has undergone radiation and hormone treatments. Just last month, when announcing his upcoming memoir, Biden stated that his treatments are going “really well.” Throughout his presidency, Biden’s health was under careful scrutiny, especially after a poor showing during a June 2024 debate against Donald Trump. Due to mounting pressure from fellow Democrats, he withdrew from the presidential race, allowing Vice President Kamala Harris to become the Democratic nominee. Trump ultimately defeated Harris in the November election.

    When elected in 2020, Biden was the oldest person to assume the U.S. presidency, serving from 2021 to 2025. He previously served as Vice President under Barack Obama from 2009 to 2017. Despite battling illness, Biden has continued to participate in public events. For instance, he attended the dedication of Obama’s presidential library in Chicago in June.

    His memoir, detailing his time in office and personal experiences, is scheduled for release on November 17.

  • Rare Family Gene May Cause Early Aggressive Prostate Cancer in Men

    Rare Family Gene May Cause Early Aggressive Prostate Cancer in Men

    Most cancers develop over many years as cellular damage gradually accumulates, with only a small percentage resulting from inherited genetic mutations passed down through families. Identifying these inherited mutations is crucial because healthy relatives can undergo testing long before any signs of cancer appear. This early detection enables physicians to implement earlier screening measures and, in some cases, take preventive steps against life-threatening illnesses.

    A recent study has revealed a previously unrecognized inherited factor linked to aggressive prostate cancer. Researchers from the University of British Columbia, along with international partners, found that rare inherited mutations in a gene called CDK12 may significantly increase risk for certain families. The team analyzed DNA from over 4,500 men diagnosed with aggressive prostate cancer. They discovered five unrelated men from different families who carried inherited CDK12 mutations. All were diagnosed with metastatic prostate cancer between ages 44 and 62, indicating that the disease had already spread at the time of diagnosis.

    For many years, scientists believed that mutations in CDK12 were random and occurred only within tumors. However, by closely examining the genetic makeup of these patients’ cancers, researchers identified a specific genetic signature showing that inherited mutations in CDK12 disable the gene’s normal function and directly contribute to cancer development.

    This discovery has the potential to change how doctors approach screening and prevention in families at risk. Although mutations in CDK12 are rare, testing relatives of affected individuals could identify those who need more vigilant and earlier prostate cancer screening. Detecting cancer before it metastasizes greatly enhances treatment success rates.

    The study also observed that several families with CDK12 mutations had relatives who had ovarian cancer, and one patient with ovarian cancer was found to carry the same genetic mutation. While more research is necessary, these findings suggest that CDK12 mutations might influence the risk of multiple types of cancer.

    Since testing for CDK12 mutations can be performed with current genetic screening methods, this discovery is likely to be integrated into routine medical practice sooner rather than later, offering high-risk families critical insights into their future health. The research was published in the journal Cancer Discovery.

    While this genetic change is extremely rare and unlikely to account for most prostate cancer cases, its importance for affected families could be immense. Early genetic screening can facilitate detection before the cancer spreads, significantly improving treatment outcomes. The study’s findings are supported by comprehensive genetic analysis of tumor samples, adding credibility to the results.

    Further research is needed to determine the prevalence of these mutations and whether they increase susceptibility to other cancers, but the ability to detect CDK12 mutations with existing tests means these findings could quickly influence clinical care.

    For those interested in cancer risk factors, recent studies have linked artificial sweeteners to increased cancer risk and explored how milk consumption impacts heart disease and cancer. Additional research on the optimal timing for vitamin intake to prevent heart disease and the benefits of vitamin D supplements in reducing cancer mortality is also available.

  • Renaming Low-Risk Prostate Cancer May Save Thousands

    Renaming Low-Risk Prostate Cancer May Save Thousands

    Scientists are exploring a provocative idea: could certain low-risk prostate cancers be reclassified to reduce unnecessary concerns? A recent UCLA-led study proposes that renaming the least aggressive form of prostate cancer might empower men to make more informed health choices and potentially save thousands of lives annually. The findings appeared in JAMA Oncology.

    Prostate cancer is prevalent, yet not all tumors act the same. Some grow quickly and spread, demanding immediate intervention, while others stay dormant for years, often remaining harmless. Grade Group 1, also known as Gleason 6, falls into this lowest-risk category. Research indicates these tumors typically do not metastasize on their own and are unlikely to pose a threat unless a more aggressive cancer develops later.

    Because of this, doctors generally recommend active surveillance—regular PSA tests, imaging, and occasional biopsies—rather than immediate surgery or radiation. This approach allows for early detection of any changes without subjecting patients to potentially life-altering treatments that can cause ongoing issues with bladder control, bowel function, and sexual health.

    However, many men get scared when they hear the word “cancer,” leading some to pursue unnecessary treatments. The study’s researchers questioned whether removing the “cancer” label could lessen fear and prevent overtreatment. Using a computer model built from U.S. health data and previous research, they examined what might happen if Grade Group 1 tumors were described as a precancerous condition instead.

    The results were promising. The model suggested that greater acceptance of PSA screening could prevent approximately 2,835 prostate cancer deaths each year. Even when factoring in the possibility that men might be less diligent about follow-up, the model still indicated a net reduction of nearly 2,400 deaths annually.

    This research also sheds light on how disease labels influence health behaviors. Dr. Scott Eggener notes that science has previously led to renaming low-risk conditions in the bladder, cervix, thyroid, and some prostate tumors once it became clear they posed little harm.

    Yet, not everyone agrees. Some experts worry that changing the terminology could lead patients to underestimate the importance of regular check-ups. Missing follow-up appointments might allow more serious cancers to develop undetected.

    The researchers addressed these concerns by testing various scenarios. Their findings remained consistent: even with less frequent follow-up and minimal increases in screening, the overall number of prostate cancer deaths was predicted to fall.

    Although this study relies on mathematical modeling rather than real-world trials, it offers a compelling perspective on an important healthcare issue. More extensive studies are necessary before any official changes are implemented.

    In summary, adopting clearer, less intimidating language in medical communications could help reduce unnecessary treatments and encourage more men to participate in prostate cancer screening programs. For further insights, explore studies on bacteria linked to aggressive prostate cancer, new strategies for treating advanced stages, and recent advancements in reducing cancer spread and improving survival with combination therapies.

    Source: UCLA

  • Scientists Discover New Health Benefit of Metformin Beyond Diabetes

    Scientists Discover New Health Benefit of Metformin Beyond Diabetes

    Credit: Unsplash+

    For many years, metformin has been the primary medication prescribed for managing type 2 diabetes. Millions of individuals take it daily to control blood sugar levels and decrease the chance of diabetes-related complications.

    Recently, researchers suggest this widely used drug might have another unexpected benefit: a potential association with a reduced risk of prostate cancer in men.

    Researchers from the University of Otago examined a decade’s worth of scientific evidence to better understand the long-term health effects of metformin. Their extensive review included studies involving approximately 2.25 million people with type 2 diabetes, making it one of the most comprehensive analyses of its kind.

    Type 2 diabetes is a persistent condition where the body cannot effectively utilize insulin. Elevated blood sugar over time increases the risk of heart disease, strokes, kidney failure, blindness, and nerve damage. Metformin primarily lowers blood sugar by decreasing liver sugar production and enhancing insulin sensitivity.

    Previous studies have indicated that individuals taking metformin often experience lower rates of cardiovascular disease and may live longer than expected. Some research also hints at benefits related to brain health. The new review corroborates these findings, noting reductions in cardiovascular issues, dementia, and overall mortality among metformin users.

    A particularly noteworthy discovery involved prostate cancer. The data indicated that men with type 2 diabetes using metformin appear less prone to developing this prevalent cancer. Although earlier research explored whether metformin might diminish risks for various types of cancer, evidence specifically linked to prostate cancer has been limited.

    Prostate cancer ranks as the second most common cancer diagnosed in men globally. Early detection often leads to successful treatment, but managing advanced stages can be challenging. As men age, the risk of prostate cancer increases, making prevention a growing concern as populations age worldwide.

    Senior researcher Associate Professor Yoram Barak expressed enthusiasm about these findings, suggesting that metformin could have broader health benefits than previously understood.

    However, he cautioned that individuals without diabetes should not start taking metformin solely to lower cancer risk. More robust evidence is needed before such practices can be recommended.

    The researchers also emphasized the importance of studying healthy aging. Advances in medicine are enabling people to live longer, yet many older adults spend their later years battling chronic diseases. Investigating whether existing medications can slow the aging process or prevent age-related illnesses could greatly enhance quality of life and reduce healthcare costs.

    There are notable limitations to this research. Since it relies on previously published studies, it can only identify associations rather than establish a cause-and-effect relationship.

    Variations in diet, physical activity, smoking habits, healthcare access, and other medications might partly explain the observed lower cancer rates. To determine whether metformin directly protects against prostate cancer, randomized clinical trials are necessary.

    Despite these constraints, the review adds to the growing evidence that metformin might provide health advantages beyond blood sugar control. Future studies will clarify whether its effects on aging and cancer risk are real and applicable to individuals without diabetes.

    If you’re interested in diabetes-related topics, consider reviewing studies about bananas and blood sugar, or how honey might help regulate blood glucose levels.

    For more health insights, explore recent research on vitamin D, which could reduce dangerous complications in diabetes, and plant-based proteins that may help reverse type 2 diabetes.

    The study was published in the journal Rejuvenation Research.

    Source: University of Otago.

  • Targeted Combo Therapy Could Prevent Aggressive Prostate Cancer Recurrence

    Targeted Combo Therapy Could Prevent Aggressive Prostate Cancer Recurrence

    A new study indicates that combining immunotherapy with radiation treatment could prolong cancer-free periods for men with highly aggressive prostate cancer, offering renewed hope for patients facing one of the most difficult types of the disease to manage.

    Research conducted by scientists at Moffitt Cancer Center and published in the Journal for ImmunoTherapy of Cancer highlights this potential breakthrough.

    Prostate cancer impacts millions globally and is one of the most common cancers among older men. While many prostate tumors grow slowly and can be effectively managed over years, some behave very differently.

    Grade Group 5 prostate cancer is recognized as one of the most aggressive forms. These tumors tend to grow rapidly, metastasize more frequently, and pose a higher risk of becoming life-threatening.

    Due to this elevated risk, doctors often employ multiple treatments simultaneously to contain the disease before it spreads further.

    In this latest research, investigators explored whether immunotherapy could enhance the effectiveness of radiation therapy.

    Unlike chemotherapy or radiation, immunotherapy doesn’t attack cancer cells directly but instead boosts the body’s immune system, helping it identify and eliminate cancer more efficiently.

    The drug used in the study was nivolumab, an immunotherapy already approved for treating various other cancers.

    Cancer cells sometimes evade immune detection by turning off immune cells through proteins called checkpoints. Nivolumab blocks one of these checkpoints, keeping immune cells active against tumor cells.

    Scientists hypothesized that combining radiation therapy with immunotherapy might produce synergistic effects. Radiation damages cancer cells and might release signals that make tumors more visible to the immune system. The goal was to administer nivolumab before and during radiation to amplify immune responses.

    The study involved 31 men diagnosed with Grade Group 5 prostate cancer. Each participant underwent an intensive treatment regimen that included hormone therapy to lower growth-stimulating hormones and two types of radiation treatments:

    – Brachytherapy: this involves placing radioactive material directly inside the prostate, allowing high doses to target the tumor precisely.
    – External beam radiation: using external machines to direct radiation at the prostate.

    Patients began nivolumab about a month before starting radiation and continued throughout their radiation therapy.

    Monitoring involved routine PSA blood tests, which measure prostate cancer activity. Elevated PSA levels can indicate the cancer’s return or progression.

    After two years, approximately 90% of the participants showed no biochemical signs of cancer recurrence. For patients with such high-risk disease, these results are encouraging.

    Furthermore, the combination appeared to be well tolerated, with no severe toxic side effects reported despite the aggressive treatment approach.

    An interesting aspect of the study was the use of a genetic biomarker called the Decipher immunosuppression score, which assesses how strongly the tumor interacts with the immune system. Patients with higher scores responded more favorably, suggesting that such biomarkers might help identify patients most likely to benefit from immunotherapy in future treatments.

    Lead researcher Kosj Yamoah explained that initiating immune activation early—before radiation damages tumor cells—was a strategic approach, aiming to help the immune system recognize and attack remaining cancer cells more effectively.

    While these findings are promising, they are still preliminary due to the small sample size and lack of a control group receiving only standard treatment. Longer follow-up is necessary to determine whether the positive effects continue over time, considering that prostate cancer can recur years after initial therapy.

    The next step involves larger, randomized trials comparing the combined approach directly against standard treatments, with hopes of identifying which patients are most likely to benefit based on tumor characteristics or biomarkers.

    Despite significant advances, aggressive prostate cancer remains a formidable challenge, as many patients experience recurrence despite intensive therapies. Combining immunotherapy with radiation is garnering increasing scientific interest because these treatments may reinforce each other’s effects, leading to better outcomes.

    This research opens the door to more personalized prostate cancer treatments, leveraging immune biomarkers and combination therapies. Although further studies are essential before altering clinical guidelines, early results suggest that activating the immune system alongside radiation could become a vital strategy against high-risk prostate cancers.

    For those interested in prostate cancer, exploring recent research on bacteria linked to aggressive forms and novel treatment strategies for advanced disease can provide valuable insights. Additional promising areas include new methods to reduce metastatic spread and treatments that combine multiple drugs to improve survival rates in advanced cases.

    Source: Moffitt Cancer Center

  • New Urine Test May Prevent Unnecessary Prostate Biopsies

    New Urine Test May Prevent Unnecessary Prostate Biopsies

    A new urine test may soon revolutionize how physicians monitor men with low-risk prostate cancer, providing a much less invasive method to determine if the disease is progressing into a more dangerous stage. Researchers have shown that this test outperforms traditional approaches such as PSA blood tests and MRI scans when it comes to identifying patients who genuinely need repeat biopsies.

    Published in The Journal of Urology, the study indicates that the test could help many men avoid unnecessary procedures while still effectively detecting cancers that become more aggressive and require treatment.

    Prostate cancer remains one of the most prevalent cancers among men worldwide. In many cases, the cancer grows slowly and may never pose a serious threat during a person’s lifetime. As a result, healthcare providers often recommend “active surveillance,” which involves closely monitoring the cancer rather than jumping straight to surgery or radiation therapy.

    This approach aims to prevent the side effects associated with aggressive treatments, including urinary problems, bowel issues, and sexual dysfunction. However, active surveillance can be stressful, involving frequent testing and repeated prostate biopsies, which require inserting needles into the prostate to collect tissue. While biopsies are common, they can cause pain, bleeding, infections, anxiety, and discomfort.

    Currently, doctors rely on PSA levels, MRI scans, and biopsies to monitor for signs that prostate cancer might be worsening. Unfortunately, these methods are not foolproof—elevated PSA levels can be caused by factors other than cancer, and MRI scans don’t always clearly reveal dangerous changes.

    The innovative test, called MyProstateScore 2.0-Active Surveillance (MPS2-AS), could provide a better solution. Instead of just blood tests or imaging, it analyzes urine samples for biomarkers associated with more aggressive cancer forms.

    Vanderbilt Health researchers tested the urine test on over 300 men diagnosed with low-grade prostate cancer (Grade Group 1) who were already on active surveillance. The goal was to determine if the test could accurately identify those who had upgraded to higher-grade cancers that need treatment, as well as those who could safely avoid another biopsy.

    Results were promising: the test correctly identified high-grade prostate cancer in 97% of cases. Notably, if a patient’s urine test was negative, there was only about a 1% chance they actually had a more dangerous cancer—highlighting the test’s high negative predictive value. This means it’s highly reliable in reassuring both doctors and patients that serious cancer is unlikely.

    Using this test, researchers estimate that up to 64% of unnecessary repeat biopsies could be avoided for men under active surveillance. Dr. Jeffrey Tosoian, an assistant professor of urology at Vanderbilt and the study’s lead author, commented that these findings suggest many men might skip invasive biopsies without missing critical cancer developments.

    The grading system for prostate cancer—using the Gleason score and Grade Group—helps estimate how aggressive the cancer may be. Higher scores typically relate to a greater likelihood of spread. Participants in this study initially had low-risk cancers with a Gleason score of 6 and Grade Group 1. The focus was on detecting whether the cancer had upgraded to Grade Group 3 or higher, which usually warrants treatment.

    This research is especially significant because many men on active surveillance grapple with anxiety and uncertainty about whether their cancer might worsen unexpectedly. The urine test offers a non-invasive way to reduce physical discomfort and emotional stress, replacing repeated needle biopsies with a simple urine sample.

    The findings also mark progress toward more personalized cancer management. Instead of a one-size-fits-all strategy, doctors could someday use such precise tools to determine who truly needs invasive procedures and who can safely be observed.

    The research team is now exploring whether similar testing could assist in other aspects of prostate cancer care, including monitoring for recurrence after treatment. Overall, the study emphasizes a delicate balance in prostate cancer screening and management—aiming to catch dangerous cancers early while avoiding unnecessary harm from overtesting and overtreatment.

    Though more validation in larger, diverse populations is necessary before the test becomes routine, experts believe these early results are encouraging and could greatly improve future prostate cancer monitoring practices.

    For those interested in prostate health updates, recent studies explore bacteria linked to aggressive prostate cancer, new strategies to treat advanced stages, methods to reduce the risk of disease spread, and the effectiveness of combination therapies that improve survival in metastatic cases.

    The study was published by Vanderbilt University.

  • Diabetes Drug Mimics Exercise Benefits for Cancer Patients

    Diabetes Drug Mimics Exercise Benefits for Cancer Patients

    A recent study suggests that metformin, a commonly used medication for type 2 diabetes, may mimic some of the effects of exercise in the body, particularly in men undergoing treatment for prostate cancer. Published in EMBO Molecular Medicine, the research sheds light on how the body manages energy and weight during cancer therapy, especially when patients are unable to stay physically active.

    Exercise is well recognized for its numerous health benefits, including weight regulation, improved blood sugar control, heart health support, and enhanced overall wellbeing. For cancer patients, it can also help alleviate treatment side effects and speed recovery. However, many patients struggle to maintain a regular exercise routine due to side effects such as fatigue, weakness, and discomfort caused by treatments like hormone therapy.

    This challenge has led scientists to ponder whether the biological processes triggered by exercise could be activated through other means. To explore this, researchers from the University of Miami Miller School of Medicine focused on metformin. They investigated a molecule called N-lactoyl-phenylalanine, or Lac-Phe, which is produced during intense physical activity when lactate—accumulating during exercise—combines with phenylalanine, a protein building block.

    Previous studies linked Lac-Phe to reduced appetite and better weight management, mirroring some effects of regular exercise. The new research revealed that metformin can increase Lac-Phe levels in prostate cancer patients even when they are not exercising. This suggests that metformin might activate similar pathways used by physical activity, offering metabolic benefits for those unable to exercise.

    The study concentrated on men undergoing hormone therapy for prostate cancer, which often disrupts metabolism and leads to weight gain, insulin resistance, and a higher risk of heart disease. Maintaining metabolic health during such treatment is crucial for both immediate wellbeing and long-term health outcomes. Results showed that Lac-Phe levels in patients taking metformin increased to levels comparable to those seen after intense exercise, despite the patients being sedentary at the time. This effect persisted even after hormone therapy started.

    However, the study also found no direct link between elevated Lac-Phe levels and a reduction in tumor growth, indicating that while metformin may support metabolic health, it doesn’t directly impact cancer progression through this pathway. Additionally, metformin influences other bodily pathways; for example, it raised levels of GDF-15, a hormone associated with appetite regulation and weight loss. Yet, Lac-Phe was more closely tied to actual changes in body weight.

    These findings offer valuable insights into how treatments affect the body and how existing drugs might be repurposed to improve overall health in cancer patients. They emphasize focusing not just on the disease itself but also on improving quality of life and bodily function during treatment.

    It’s important to note that metformin isn’t a substitute for exercise, which provides benefits beyond what medication can offer. More extensive research is needed to validate these findings across larger and more diverse populations.

    Overall, this study highlights a significant advance: a well-known, accessible drug like metformin may help support metabolic health in patients unable to engage in physical activity, potentially improving their comfort and resilience during cancer treatment.

  • New Drug Combo Shows Promise in Slowing Aggressive Prostate Cancer

    New Drug Combo Shows Promise in Slowing Aggressive Prostate Cancer

    A recent international study has revealed that combining two cancer drugs could significantly slow the progression of a particularly dangerous form of prostate cancer in certain men. Led by researchers at University College London (UCL), the study involved hundreds of patients from multiple countries.

    Published in the journal Nature Medicine, these findings offer renewed hope for patients with prostate cancer that harbors specific genetic mutations, making the disease more difficult to treat.

    Prostate cancer ranks among the most common cancers affecting men. The prostate, a small gland located below the bladder, plays a role in semen production. As men age, prostate cells can grow uncontrollably, forming tumors. Often, prostate cancer develops slowly and can be managed effectively with treatment.

    However, some cases become aggressive, spreading to areas like bones and lymph nodes. Once the cancer metastasizes, treatment becomes more challenging and the risk to life increases.

    Researchers have long sought to understand why some prostate tumors become more aggressive than others. A key clue involves a group of genes responsible for repairing damaged DNA, known as homologous recombination repair (HRR). These genes act as a cellular repair crew, fixing DNA errors that could otherwise trigger cancer. When these genes function properly, they help prevent cancer from developing. But when mutated or damaged, DNA repair is impaired, leading to faster cancer growth and spread.

    Approximately 25% of men with advanced prostate cancer carry mutations in HRR-related genes, including well-known ones like BRCA1 and BRCA2—genes also linked to breast and ovarian cancers. Other important genes, such as CHEK2 and PALB2, can also contribute. When these genes aren’t working correctly, the cancer tends to become more aggressive and less responsive to standard treatments.

    To explore new treatment options, scientists conducted the large-scale AMPLITUDE trial, a Phase III clinical study. This phase typically tests a promising treatment in a broad patient population to verify its safety and effectiveness.

    The trial included 696 men from 32 countries, all with metastatic prostate cancer who had not yet started specific treatment for this stage. The average age of participants was 68, and every participant had a mutation in an HRR gene.

    Participants were divided into two groups. One received the standard treatment, which includes abiraterone acetate and prednisone—medications that slow cancer growth by lowering male hormone levels that fuel tumor development. The other group received the same standard treatment plus niraparib, a targeted drug known as a PARP inhibitor.

    PARP inhibitors are designed to exploit weaknesses in cancer cells with DNA repair deficiencies. By blocking another repair pathway, these drugs cause cancer cells to accumulate lethal levels of DNA damage, leading to cell death. Healthy cells are less affected because their repair mechanisms remain functional.

    The study was double-blind, meaning neither the patients nor the doctors knew who received niraparib or a placebo, reducing bias and increasing the reliability of results.

    After a median follow-up of about 30.8 months, the data showed a clear benefit for those on the combination therapy. Patients taking niraparib with standard treatment had a 37% lower chance of their cancer worsening compared to those on standard therapy alone.

    The most remarkable results appeared in patients with mutations in BRCA1 or BRCA2. In this subgroup, the risk of disease progression dropped by nearly half—about 48%. This suggests that the drug combination could be especially potent for patients with these specific genetic weaknesses.

    Additionally, symptom worsening took longer in the niraparib group. Only 16% experienced significant symptom progression, compared to 34% in the placebo group. This indicates that many patients maintained their quality of life longer with the combination treatment.

    There were signs that the new therapy might boost overall survival, but longer follow-up is necessary to confirm this potential benefit.

    As with many cancer treatments, side effects were more common among patients taking niraparib. Some experienced anemia, a condition where red blood cell levels are too low, and high blood pressure was also reported more frequently. About a quarter of patients needed blood transfusions during treatment, and there were slightly more treatment-related deaths in the niraparib group, though numbers remained small. Most patients were still able to continue treatment despite these issues.

    The study underscores the importance of genetic testing in cancer care. By identifying HRR gene mutations early, clinicians can better determine which patients are most likely to benefit from targeted therapies like niraparib.

    Annually, around 1.5 million men are diagnosed with prostate cancer worldwide. In the United States alone, over 56,000 men are diagnosed each year, with roughly 12,000 deaths. Because of its prevalence, even modest advances in treatment can significantly impact public health.

    The AMPLITUDE trial was sponsored by Janssen Research and Development, part of Johnson & Johnson. These results suggest that combining genetic-driven therapies with hormone treatments could be a key step toward personalized cancer care.

    Overall, the research demonstrates that adding niraparib to standard therapy can delay disease progression in men with certain genetic forms of advanced prostate cancer. Still, potential risks and side effects should be carefully considered. More long-term studies are vital to determine if this approach improves overall survival and to identify which patients are the most suitable candidates.

    Despite the need for further research, these findings mark an important milestone in tailoring cancer treatments based on individual genetic profiles.

  • Biden Receives Radiation Treatment for Prostate Cancer, Spokesperson Confirms

    Biden Receives Radiation Treatment for Prostate Cancer, Spokesperson Confirms

    Former US President Joe Biden is currently undergoing radiation and hormone therapy to treat prostate cancer, spokesperson says. The diagnosis was announced in May, revealing an aggressive form of the cancer that had spread to his bones. Biden, who is 82, experienced urinary symptoms and a prostate nodule prior to the diagnosis.

    In a message shared on X, the president reflected on cancer’s universal impact, mentioning his son Beau Biden’s death from cancer in 2015. “Cancer touches us all. Like many of you, Jill and I have learned that we are strongest in the broken places,” he stated. He also expressed gratitude for the support from the public.

    Biden’s health has been a topic of concern, especially amid a recently published book that highlighted his declining physical condition during his campaign last year for a second term. Following a poor debate performance against Donald Trump in July 2024, Biden decided to withdraw from the race and endorsed Vice President Kamala Harris, who ultimately lost to Trump, who assumed his second term in January.

    Prostate cancer is the most prevalent cancer among men in the U.S., according to the American Cancer Society. It is notably common in older men; about 80% of those over 80 have some cancerous cells in their prostate. While early detection greatly increases treatment success, it remains the second leading cause of cancer-related death among men. Hormone therapy, often used to reduce tumor size and slow cancer growth, is a standard treatment but does not offer a cure.

    Meanwhile, Donald Trump, at 79—the oldest person ever elected president—had his second medical checkup of the year, with doctors deeming him to be in “excellent overall health.”

  • Biden Shares Optimism Following Cancer Diagnosis

    Biden Shares Optimism Following Cancer Diagnosis

    Former US President Joe Biden arrives at Saint Joseph in Wilmington, Delaware, on May 30, 2025. — AFP

    WILMINGTON: Joe Biden, the former President of the United States, expressed a sense of “optimism” regarding his future during a press briefing on Friday. This was his first public statement since disclosing his battle with an aggressive form of prostate cancer.

    “The prognosis looks positive. We’re making progress with everything. I feel good,” said Biden, who is 82 years old, after an event in Delaware that acknowledged the Memorial Day holiday, which took place on Monday.

    Earlier this month, his office revealed that he has been diagnosed with prostate cancer, specifically a Gleason score of nine, categorizing it as severe.

    The seasoned Democrat shared that he has established a treatment plan, confidently stating, “I expect we’re going to overcome this.”

    “The cancer hasn’t affected any organs; my bones are healthy, and it hasn’t spread. So, I’m feeling optimistic,” he noted.

    The former president’s age and health were significant topics during the 2024 election, especially after a challenging debate with Donald Trump, which led him to withdraw from the race for a second term.

    Despite initial reports that his cancer had metastasized to his bones, Biden reassured the press by saying, “There’s a sense of optimism regarding my diagnosis. In fact, I’m working with one of the leading surgeons worldwide.”

    The political implications surrounding Biden’s abandoned candidacy have ignited controversy, especially following the release of the book “Original Sin,” which claims that his administration concealed signs of cognitive decline during his presidency.

    When questioned about the backlash, Biden replied with humor, saying, “People think I’m mentally incompetent and can’t walk.” He also expressed no regrets about running for a second term, asserting that his Democratic challengers opted not to contest him because “they knew I would have won.”

    In earlier statements in New Castle, Delaware, Biden referred to his presidency as his greatest privilege and advocated for improved treatment of veterans.

    He dedicated poignant remarks to commemorate the tenth anniversary of his son, Beau Biden, a National Guard veteran, who passed away from brain cancer at the age of 46, stating, “For our family, this day marks the 10th anniversary of losing Beau, who served for a year in Iraq. Honestly, it’s a difficult day.”

  • Joe Biden Expresses Gratitude to Supporters After Cancer News

    Joe Biden Expresses Gratitude to Supporters After Cancer News

    President Biden Thanks Americans Following Cancer Diagnosis

    US President Joe Biden addresses the media after a closed Senate Democratic Caucus lunch at the US Capitol in Washington, DC, on March 2, 2023. — Reuters

    WASHINGTON: On Monday, President Joe Biden expressed his heartfelt thanks to the American public for their “love and support” after announcing his recent diagnosis of prostate cancer.

    His diagnosis of an “aggressive” form of prostate cancer, which has spread to his bones, was made public over the weekend. This news prompted a wave of support from various quarters, including Biden’s political opponent, former President Donald Trump, Vice President Kamala Harris, and many everyday Americans.

    Biden, 82, shared a message on X, noting, “Cancer affects us all. Like many of you, Jill and I have come to understand that we find our strength in our most difficult moments.” He included a photo with his wife, Jill. “Thank you for surrounding us with your love and support,” he added.

    According to his office, Biden was diagnosed on Friday after experiencing urinary symptoms and the discovery of a prostate nodule. “While this represents a more aggressive variant of the disease, the cancer appears to be hormone-sensitive, allowing for effective management. The President and his family are currently discussing treatment plans with his doctors,” the statement also said.

    Trump, who has frequently criticized Biden’s cognitive abilities and presidential record, expressed his sadness over the news. He posted on Sunday, “We send our warmest wishes to Jill and the family, and wish Joe a quick and successful recovery.”

    Kamala Harris, who stepped in as the Democratic nominee when Biden withdrew from last year’s presidential race, remarked, “Joe is a fighter. I know he will tackle this challenge with the strength, resilience, and optimism that have always characterized his life and leadership.”

    About Prostate Cancer

    Prostate cancer is the most commonly diagnosed cancer among men in the United States. According to the American Cancer Society (ACS), one in eight men will receive a diagnosis during their lifetime. If detected early, it can often be treated successfully, yet it remains the second leading cause of cancer deaths among men.

    Hormone therapy is a common treatment option aimed at shrinking tumors and slowing cancer progression, though it is not a definitive cure. Biden’s cancer diagnosis includes a “Gleason score of nine (Grade Group five),” which indicates a particularly aggressive form of the disease, according to the ACS.

    Biden’s health has become a significant topic in the ongoing 2024 presidential race, where Trump and his conservative allies have repeatedly critiqued the incumbent’s cognitive abilities. After a challenging debate performance against Trump, Biden opted to withdraw from the campaign for a second term.

    Biden’s life has been marked by deep personal loss. In 1972, he lost his first wife and infant daughter in a tragic car accident. His son Beau passed away from an aggressive brain cancer at the age of 46 in 2015.

    Following Beau’s death, then-President Barack Obama initiated a “cancer moonshot” initiative aimed at combating cancer across the U.S., putting Biden, his vice president, in charge of leading the effort. “It’s personal for me,” Biden stated at the time.

  • Joe Biden’s Aggressive Prostate Cancer Diagnosis: Official Statement

    Joe Biden’s Aggressive Prostate Cancer Diagnosis: Official Statement

    Former US President Joe Biden at a White House event in Washington, D.C., October 31, 2023. —Reuters

    Former President Joe Biden has been diagnosed with an aggressive strain of prostate cancer that has metastasized to his bones, his office announced on Sunday.

    On Friday, the 82-year-old Democrat received a diagnosis indicating “prostate cancer with metastasis to the bone,” the statement revealed.

    “While this signifies a more aggressive type of the disease, the cancer appears to be hormone-sensitive, which allows for effective management,” the statement added.

    The diagnosis followed Biden experiencing worsening urinary symptoms and a recent examination that revealed a prostate nodule, the office noted.

    This revelation comes as Biden asserts that he believes he could have won the 2024 presidential election, despite having exited the race amid concerns about his age and capabilities.

    His vice president, Kamala Harris, ultimately lost to Republican nominee Donald Trump.

    Last week, a newly released audio recording of Biden slightly struggling with his words and recalling key events reignited discussions about his mental fitness while still serving in office.

    Biden’s son, Beau Biden, tragically passed away from brain cancer in 2015.